Clinical Trial Update: Bortezomib in Treating Patients With Unresectable Locally Advanced or Metastatic Adenocarcinoma of the Bile Duct or Gallbladder [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating Bortezomib in unresectable or metastatic adenocarcinoma of the bile duct or gallbladder was terminated; results were posted in 2017.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Extrahepatic Cholangiocarcinoma
• Gallbladder Cancer
• Hepatocellular Carcinoma

Drugs mentioned

• Bortezomib (bortezomib)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Adenocarcinoma of the Extrahepatic Bile Duct, Adenocarcinoma of the Gallbladder | Phase 2 | Status: TERMINATED | Results posted: 2017-06-14